(R)-(+)-Etomoxir sodium saltCarnitine palmitoyltransferase I (CPT1) inhibitor CAS# 828934-41-4 |
- Anguizole
Catalog No.:BCC1365
CAS No.:442666-98-0
- Asunaprevir (BMS-650032)
Catalog No.:BCC1374
CAS No.:630420-16-5
- Balapiravir
Catalog No.:BCC1396
CAS No.:690270-29-2
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 828934-41-4 | SDF | Download SDF |
PubChem ID | 57345784 | Appearance | Powder |
Formula | C15H18ClNaO4 | M.Wt | 320.74 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Synonyms | (+)-Etomoxir sodium salt | ||
Solubility | DMSO : 100 mg/mL (311.78 mM; Need ultrasonic) H2O : 5 mg/mL (15.59 mM; Need ultrasonic) | ||
Chemical Name | sodium;(2R)-2-[6-(4-chlorophenoxy)hexyl]oxirane-2-carboxylate | ||
SMILES | C1C(O1)(CCCCCCOC2=CC=C(C=C2)Cl)C(=O)[O-].[Na+] | ||
Standard InChIKey | RPACBEVZENYWOL-XFULWGLBSA-M | ||
Standard InChI | InChI=1S/C15H19ClO4.Na/c16-12-5-7-13(8-6-12)19-10-4-2-1-3-9-15(11-20-15)14(17)18;/h5-8H,1-4,9-11H2,(H,17,18);/q;+1/p-1/t15-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Inhibitor of carnitine palmitoyltransferase I (CPT1); inhibits β-oxidation in mitochondria. Shown to inhibit cardiolipin biosynthesis from exogenous fatty acid in H9c2 cells. |
(R)-(+)-Etomoxir sodium salt Dilution Calculator
(R)-(+)-Etomoxir sodium salt Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1178 mL | 15.589 mL | 31.1779 mL | 62.3558 mL | 77.9448 mL |
5 mM | 0.6236 mL | 3.1178 mL | 6.2356 mL | 12.4712 mL | 15.589 mL |
10 mM | 0.3118 mL | 1.5589 mL | 3.1178 mL | 6.2356 mL | 7.7945 mL |
50 mM | 0.0624 mL | 0.3118 mL | 0.6236 mL | 1.2471 mL | 1.5589 mL |
100 mM | 0.0312 mL | 0.1559 mL | 0.3118 mL | 0.6236 mL | 0.7794 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
(R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is a potent inhibitor of carnitine palmitoyltransferase-I (CPT-1).
In Vitro:(R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir binds irreversibly to the catalytic site of CPT-1 inhibiting its activity, but also upregulates fatty acid oxidation enzymes. Etomoxir is developed as an inhibitor of the mitochondrial carnitine palmitoyltransferase-1 (CPT-1) located on the outer mitochondrial membrane. Etomoxir, in the liver can act as peroxisomal proliferator, increasing DNA synthesis and liver growth. Thus, etomoxir, in addition of being a CPT1 inhibitor could be considered as a PPARalpha agonist[1]. Etomoxir is a member of the oxirane carboxylic acid carnitine palmitoyl transferase I inhibitors and has been suggested as a therapeutic agent for the treatment of heart failure. Acute Etomoxir treatment irreversibly inhibits the activity of carnitine palmitoyltransferase I. As a result, fatty acid import into the mitochondria and β-oxidation is reduced, whereas cytosolic fatty acid accumulates and glucose oxidation is elevated. Prolonged incubation (24 h) with Etomoxir produces diverse effects on the expression of several metabolic enzyme[2].
In Vivo:(R)-(+)-Etomoxir sodium salt is R-form of Etomoxir sodium salt. Etomoxir is an inhibitor of free fatty acid (FFA) oxidation-related key enzyme CPT1. P53 interacts directly with Bax, which is inhibited by Etomoxir, further confirming the direct interaction of P53 and Bax, and the involvement of FAO-mediated mitochondrial ROS generation in db/db mice[3]. Rats are injected daily with Etomoxir, a specific CPT-I inhibitor, for 8 days at 20 mg/kg of body mass. Etomoxir-treated rats display a 44% reduced cardiac CPT-I activity. The treatment of Lewis rats for 8 days with 20 mg/kg Etomoxir does not alter blood glucose, which is in line with comparable etomoxir-feeding studies. Similarly, Etomoxir feeding does not affect general growth characteristics such as gain in body mass, nor does it affect hindlimb muscle mass. However, heart mass and liver mass are both significantly increased by 11% in Etomoxir-treated rats[4].
References:
[1]. Rupp H, et al. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure. Herz. 2002 Nov;27(7):621-36.
[2]. Xu FY, et al. Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.
J Lipid Res. 2003 Feb;44(2):415-23.
[3]. Li J, et al. FFA-ROS-P53-mediated mitochondrial apoptosis contributes to reduction of osteoblastogenesis and bone mass in type 2 diabetes mellitus. Sci Rep. 2015 Jul 31;5:12724.
[4]. Luiken JJ, et al. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates. Biochem J. 2009 Apr 15;419(2):447-55.
- 2,3-Dihydroisoginkgetin
Catalog No.:BCN4035
CAS No.:828923-27-9
- Cyclo(Tyr-Leu)
Catalog No.:BCN2432
CAS No.:82863-65-8
- Echinacoside
Catalog No.:BCN4953
CAS No.:82854-37-3
- Pingpeimine B
Catalog No.:BCN8408
CAS No.:82851-52-3
- Pingpeimine A
Catalog No.:BCN8407
CAS No.:82841-67-6
- Perindopril
Catalog No.:BCC4223
CAS No.:82834-16-0
- cGMP Dependent Kinase Inhibitor Peptide
Catalog No.:BCC8084
CAS No.:82801-73-8
- H-D-HoPhe-OH
Catalog No.:BCC3239
CAS No.:82795-51-5
- Nefazodone hydrochloride
Catalog No.:BCC7479
CAS No.:82752-99-6
- DCPIB
Catalog No.:BCC7105
CAS No.:82749-70-0
- 6,7-Dihydroxy-4-(Trifluoromethyl)Coumarin
Catalog No.:BCC8286
CAS No.:82747-36-2
- Perforatumone
Catalog No.:BCN4370
CAS No.:827319-50-6
- 3-Oxo-24,25,26,27-tetranortirucall-7-en-23,21-olide
Catalog No.:BCN1338
CAS No.:828935-47-3
- Fmoc-Osu
Catalog No.:BCC2804
CAS No.:82911-69-1
- 7,4'-Dihydroxy-8-methylflavan
Catalog No.:BCN6841
CAS No.:82925-55-1
- CI 898 trihydrochloride
Catalog No.:BCC7248
CAS No.:82952-64-5
- Nafamostat Mesylate(FUT-175)
Catalog No.:BCC1228
CAS No.:82956-11-4
- 11-O-Galloylbergenin
Catalog No.:BCN6637
CAS No.:82958-44-9
- 4-O-Galloylbergenin
Catalog No.:BCN6643
CAS No.:82958-45-0
- Tolrestat
Catalog No.:BCC4084
CAS No.:82964-04-3
- 4-Aminoantipyrine
Catalog No.:BCC8683
CAS No.:83-07-8
- Phenindione
Catalog No.:BCC4699
CAS No.:83-12-5
- 1-Indanone
Catalog No.:BCN2245
CAS No.:83-33-0
- Methylprednisolone
Catalog No.:BCC2256
CAS No.:83-43-2
Etomoxir mediates differential metabolic channeling of fatty acid and glycerol precursors into cardiolipin in H9c2 cells.[Pubmed:12576524]
J Lipid Res. 2003 Feb;44(2):415-23.
We examined the effect of etomoxir treatment on de novo cardiolipin (CL) biosynthesis in H9c2 cardiac myoblast cells. Etomoxir treatment did not affect the activities of the CL biosynthetic and remodeling enzymes but caused a reduction in [1-14C]palmitic acid or [1-14C]oleic acid incorporation into CL. The mechanism was a decrease in fatty acid flux through the de novo pathway of CL biosynthesis via a redirection of lipid synthesis toward 1,2-diacyl-sn-glycerol utilizing reactions mediated by a 35% increase (P < 0.05) in membrane phosphatidate phosphohydrolase activity. In contrast, etomoxir treatment increased [1,3-3H]glycerol incorporation into CL. The mechanism was a 33% increase (P < 0.05) in glycerol kinase activity, which produced an increased glycerol flux through the de novo pathway of CL biosynthesis. Etomoxir treatment inhibited 1,2-diacyl-sn-glycerol acyltransferase activity by 81% (P < 0.05), thereby channeling both glycerol and fatty acid away from 1,2,3-triacyl-sn-glycerol utilization toward phosphatidylcholine and phosphatidylethanolamine biosynthesis. In contrast, etomoxir inhibited myo-[3H]inositol incorporation into phosphatidylinositol and the mechanism was an inhibition in inositol uptake. Etomoxir did not affect [3H]serine uptake but resulted in an increased formation of phosphatidylethanolamine derived from phosphatidylserine. The results indicate that etomoxir treatment has diverse effects on de novo glycerolipid biosynthesis from various metabolic precursors. In addition, etomoxir mediates a distinct and differential metabolic channeling of glycerol and fatty acid precursors into CL.
Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor.[Pubmed:1531968]
FASEB J. 1992 Mar;6(6):2349-53.
To examine the signals regulating cardiac growth and molecular structure of subcellular organelles, cardiac hypertrophy was induced in rats by constriction of the abdominal aorta for 12-13 wk or by treatment with a carnitine palmitoyltransferase I inhibitor, etomoxir (12-15 mg/kg body wt) for 12-13 wk. In contrast to pressure overload, etomoxir redistributed the myosin isozyme population from V3 to V1 and increased the sarcoplasmic reticulum (SR) Ca(2+)-stimulated ATPase activity. When rats with pressure-overloaded hearts were treated with etomoxir, the cardiac hypertrophy was increased whereas the shift in myosin isozymes from V1 to V3 was prevented and the depression in SR Ca(2+)-stimulated ATPase activity was reversed. Plasma thyroid hormone and insulin concentrations were not altered but triglyceride concentrations were reduced in etomoxir-treated rats with pressure overload. The data demonstrate a dissociation between cardiac muscle growth and changes in subcellular organelles and indicate that a shift in myocardial substrate utilization may represent an important signal for molecular remodeling of the heart.
Stereospecificity of the inhibition by etomoxir of fatty acid and cholesterol synthesis in isolated rat hepatocytes.[Pubmed:1930298]
Biochem Pharmacol. 1991 Oct 9;42(9):1717-20.
The racemates of substituted 2-oxiranecarboxylates are potent inhibitors of fatty acid oxidation and fatty acid and cholesterol synthesis. We show in the accompanying paper [Agius L, Peak M and Sherratt HSA, Biochem Pharmacol 42: 1711-1715, 1991] that only the R-enantiomer of etomoxir, a potent hypoglycaemic compound, inhibits fatty acid oxidation in hepatocytes. We demonstrate in this paper that although the R-enantiomer of etomoxir is esterified to its CoA-ester more readily than the S-enantiomer, both the R- and S-enantiomers are equally potent inhibitors of fatty acid and cholesterol synthesis from acetate in rat hepatocytes. The inhibition of fatty acid synthesis is not due to direct inhibition of fatty acid synthetase and the inhibition of cholesterol synthesis occurs at a site proximal to formation of mevalonate. Since the S-enantiomer inhibits fatty acid and cholesterol synthesis but not fatty acid oxidation the inhibition of the biosynthetic pathways is not coupled to inhibition of fatty acid oxidation.